SCHEMBL1630682

SCHEMBL1630682

O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(OC(F)(F)F)cc1)N1CCCC1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
NR3C1 P04150 2/20 0.47
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
HCRTR2 O43614 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
PKM P14618 1/20 0.43
OXTR P30559 1/20 0.43
AVPR1A P37288 1/20 0.43
PGR P06401 1/20 0.43
SERPINE1 P05121 1/20 0.42
LMNA P02545 3/20 0.42
HTT P42858 2/20 0.42
ALOX5 P09917 1/20 0.42
GAA P10253 1/20 0.42
HSD11B1 P28845 1/20 0.41
MAPT P10636 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630715 0.92 CRHBP (0.45) CRHBPCRHR2NR3C1KEAP1NFE2L2
SCHEMBL1630616 0.90 CRHBP (0.53) CRHBPCRHR2NR3C1KEAP1NFE2L2
SCHEMBL1629236 0.89 CRHBP (0.56) CRHBPCRHR2KEAP1NFE2L2NPSR1
SCHEMBL1629267 0.88 CRHBP (0.47) CRHBPCRHR2NR3C1NPSR1PKM
SCHEMBL3422507 0.88 CRHBP (0.51) CRHBPCRHR2KMT2ANPSR1OXTR
SCHEMBL1630642 0.88 CRHBP (0.51) CRHBPCRHR2KMT2ANPSR1OXTR
SCHEMBL1919721 0.87 CRHBP (0.38) CRHBPCRHR2NR3C1KEAP1NFE2L2
SCHEMBL1630968 0.86 OXTR (0.53) CRHBPCRHR2KEAP1NFE2L2MEN1
SCHEMBL8060525 0.86 CRHBP (0.55) CRHBPCRHR2KMT2ANPSR1PKM
SCHEMBL3423076 0.84 CRHBP (0.49) CRHBPCRHR2KEAP1NFE2L2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPSR1 CRHBP 170/4885CRHR2 14/4885NR3C1 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.